



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 29th July, 2022

Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza, 05th Floor,
Plot No: C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400051

Sub: Intimation U/R 30 of the SEBI (LODR) Regulations 2015- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

**Shilpa Medicare Limited, Unit III, Advanced Analytical Characterization Laboratory clears
US FDA Remote Record Review.**

Dear Sir / Madam,

This is to inform you that US FDA has concluded Remote Record Review of Shilpa Medicare Limited ('SML' or 'the Company'), Unit III, **Advanced Analytical Characterization Laboratory** situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th Nov 2021.

The facility is designed with advanced analytical equipment to provide testing services such as *In-vitro* Permeation testing, Nitrosamine testing, Elemental Impurity testing, Extractable & Leachable testing, Glass Delamination testing etc.

This is for your information and doing the needful.

For **SHILPA MEDICARE LIMITED**

Ritu Tiwary
Company Secretary & Compliance Officer